Multi-dose pre-clinical studies in RAT for E1-targeting antisense oligonucleotides
Ended Project Grant Awarded Last action
- Award ID
- R43NS113643
- Recipient
-
Shift Pharmaceuticals Holdings, Inc. UEI L5YJHR8PKA96
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $228,113
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Place of performance
- Columbia, MO 65203, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $228,113 |
Quick answers
Who received award R43NS113643?
R43NS113643 was awarded to Shift Pharmaceuticals Holdings, Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 16, 2019.
How much is award R43NS113643 worth?
$228,113 has been obligated on R43NS113643.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award